“Doctors Gladyshev and Strauss are pioneers in their fields,” LongeVC Managing Partner Sergey Jakimov said. “We are incredibly honored to have their aging and cellular rejuvenation expertise on our Advisory Board and look forward to their contributions to our portfolio companies.”
Gladyshev is a professor of medicine at Harvard Medical School and Director of Redox Medicine at Brigham and Women's Hospital. He leads a broad program on aging, longevity and rejuvenation using computational and experimental approaches. Gladyshev is a National Academy of Sciences member, has won many awards for his work and has published more than 400 scientific articles.
“I am glad to join the LongeVC Advisory Board and contribute to funding projects that will advance our understanding of longevity and aging,” Gladyshev said. “Considerable progress is being made in the field; LongeVC helps to make this possible by supporting early-stage companies.”
Strauss is the Director of the Neonatology Department and NICU at Sheba Medical Center near Tel Aviv, Israel. Her primary research areas include hemostasis and coagulation in preterm infants, and she advises individuals on cell rejuvenation and longevity at the forthcoming academic longevity center at Sheba Medical Center. Strauss holds an MSc in Healthcare Management from Harvard University and an MD from Technion-Israel Institute of Technology.
“LongeVC is uniquely positioned to invest in biotech and longevity companies that other investment bodies would traditionally overlook as being too risky,” Strauss said. “I am eager to join my esteemed colleagues on the LongeVC Advisory Board and share my knowledge to enhance their scientific review process.”
LongeVC invests in founders and companies across the biotech and longevity spaces. Previous investments include AOA Dx, Turn Biotechnologies, PreComb Therapeutics, First Longevity, Longenesis and more.
Press Contact:
Rachel Pipan, +31 06 422 13615, press@longevc.com
About LongeVC
LongeVC is an international venture capital firm investing in visionary biotech companies and founders. Focusing on seed and early-stage investment, LongeVC’s mission is to bring to market breakthrough biotech that will change lives and transform the nature of our health. Its portfolio companies are deploying AI to find new treatments for chronic illnesses, developing SaaS tools to accelerate life-changing medical research and more. LongeVC is proud to work with its highly involved and expert advisors, investors and partners to achieve this mission and shape the future of biotech. Learn more about LongeVC portfolio companies and join the fund as an investor at www.longevc.com.